Underrepresentation has an address.
FDA Diversity Action Plans make inclusion a requirement. The shift to community-based and decentralized sites makes it a geography problem. The layer that finds underrepresented populations — and proves they were reached — barely exists. That's the layer we built.
Three questions trial teams can't answer today.
Where do underrepresented, trial-eligible populations actually live?
- Ranked geographies for sites and community partnerships, based on where unreached eligible populations actually live.
What stands between them and a site?
- Tract-level maps of who current trial infrastructure can't reach — transportation gaps, distance, infrastructure.
Did outreach, enrollment, and retention reach them?
- Inclusion benchmarks measured comparably across geographies — so inclusion is proven, not promised.
The DAP report is the product.
FDA Diversity Action Plans don't ask what you intended — they ask what you did, where, and how you know. Every Variate answer ships with a receipt: the question, the variables (with vintages), the weights, the counts. Outreach becomes a documented, auditable artifact your regulatory team can file.
Built on real data, answered in plain English.
200+ federal health and social variables — including tract-level disease prevalence for asthma, COPD, and arthritis (CDC PLACES) — fused with social vulnerability, transportation, and health-infrastructure data. Population math done properly: never county averages smeared across empty space. And when the model is unsure, it says so, and a human decides.